223 results about "Pulmonary circulation diseases" patented technology

The present invention encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor, said compound administered in an amount effective for treating said immunoregulatory abnormality. Pharmaceutical compositions are included. The invention also encompasses a method of identifying candidate compounds that are agonists of the S1P1/Edg1 receptor and which possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor. The invention further encompasses a method of treating a respiratory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said respiratory disease or condition, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor.

The present invention relates to pharmaceutical compositions for the sustained release of pharmacologically active compounds and methods of their manufacture and use. Sustained release times of 10-12 days have been achieved with the present invention. The present invention provides microcrystal compositions. The microcrystals comprise pharmacologically active compounds and are contained within a phospholipid layer which contains a unique combination of phospholipids. The present invention may be applied to a wide range of pharmaceutical compositions which may be rendered suitable for injection. The microcrystals are of varying sizes. At least 50 percent of the microcrystals are from 0.5 mum to about 3.0 mum in diameter, at least ten percent of the microcrystals are from about 3.0 mum to about 10 mum in diameter, and the composition contains microcrystals which are greater than 10 mum in diameter. In preferred embodiments, at least about 1% of the microcrystals are greater than 10 mum in diameter. The compositions and methods are useful for treating respiratory diseases, infections, inflammation, and pain in a variety of mammals. The compounds and methods are also able to sharply reduce the toxicity of drug compounds.

The invention discloses a Chinese medicinal herb additive for egg chickens and application. The Chinese medicinal herb additive comprises membranous milkvetch root, eucommia bark, honeysuckle, jiuyue, Weeping Forsythiae Capsule, szechwon tangshen root, sanguisorba, hawthorn, Indian Buead, officinal magnolia bark, Chinese pulsatilla root, giant knotweed rhizome, ricepaperplant pith, largehead atractylodes rhizome, tangerine peel, malt, indigowoad root, swordlike atractylodes rhizome, indigowoad leaf, three immortals, liquorice, cyrtomium fortune, nutgrass galingale rhizome, chatoyancy, calamus and pinellia tuber, and mixture of the compositions is added with calcium bicarbonate, phytase, vitamin E and methionine. The Chinese medicinal herb additive effectively promotes absorption of nutrient, can prevent and control diseases, strengthen quality of eggshells, reduce the broken egg rate and soft-shell eggs, abnormal eggs and sand shell eggs, can effectively prevent bird flu, prevent and control diseases such as laxness, feather pecking, hair shedding, anus pecking, salpingitis, respiratory disease and the like, can achieve good effect with a dosage of about 4 percent, cannot damage physiological functions of the egg chickens, and can prolong egg laying peak season, improve color of the eggshells and the laying rate by 8 to 20 percent, and increase weight of eggs.

Combinations comprising (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.

The invention discloses a Chinese medicinal herb additive for egg ducks and application thereof. The Chinese medicinal herb additive comprises amur corktree bark, eucommia bark, honeysuckle, szechwon tangshen root, sanguisorba, hawthorn, Indian Buead, officinal magnolia bark, Chinese pulsatilla root, giant knotweed rhizome, ricepaperplant pith, largehead atractylodes rhizome, tangerine peel, malt, indigowoad root, swordlike atractylodes rhizome, indigowoad leaf, three immortals, liquorice, cyrtomium fortune, nutgrass galingale rhizome, chatoyancy and calamus, and mixture of the compositions is added with calcium bicarbonate, phytase, vitamin E and methionine. The Chinese medicinal herb additive effectively promotes absorption of nutrient, can prevent and control diseases, strengthen quality of eggshells, reduce the broken egg rate and soft-shell eggs, abnormal eggs and sand shell eggs, can effectively prevent bird flu, prevent and control diseases such as laxness, feather pecking, hair shedding, anus pecking, salpingitis, respiratory disease and the like, can achieve good effect with a dosage of about 4 percent, cannot damage physiological functions of the egg ducks, and can prolong egg laying peak season, improve color of the eggshells and the laying rate by 9 to 20 percent, and increase weight of eggs.

The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., Pd(II)-, Ni(II)-, or Fe(II)-ligand of Formula (A)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers Y. The provided supramolecular complexes are able to form gels (e.g., hydrogels). The gels are suprametallogels and exhibited excellent mechanical properties without sacrificing self-healing and showed high robustness and storage modulus. The present disclosure further provides compositions (e.g., gels) that include the nanostructures or supramolecular complexes and optionally an agent (e.g., small molecule), where the nanostructures and the nanostructure moieties of the supramolecular complexes may encapsulate and slowly release the agent. The nanostructures, supramolecular complex, and compositions may be useful in delivering an agent to a subject, tissue, or cell, as super-absorbent materials, and in treating a disease (e.g., a genetic diseases, proliferative disease (e.g., cancer or benign neoplasm), hematological disease, neurological disease, gastrointestinal disease (e.g., liver disease), spleen disease, respiratory disease (e.g., lung disease), painful condition, genitourinary disease, musculoskeletal condition, infectious disease, inflammatory disease, autoimmune disease, psychiatric disorder, or metabolic disorder).

It is an object of the present invention to provide an ejection liquid (liquid composition) which can be stably ejected as a liquid containing an effective ingredient for treating respiratory disease from an ejection opening provided to an ejection device. A specific surface-active compound is added to an ejection liquid containing an effective ingredient for treating respiratory disease. An ejection liquid which is used for stably ejecting a solution containing an active ingredient for treating respiratory disease according to the principle of an ink jet system, a method which is suitable for ejecting this ejection liquid, and an ejection device are provided. The ejection liquid includes an active ingredient for treating j respiratory disease, a specific surface-active compound, and a liquid medium and is ejected from an ejection opening by an ink jet system.

The invention relates to the field of pharmaceutical preparations and particularly relates to a slow-release micropill preparation containing enrofloxacin and a preparation method of the preparation. The slow-release micropill provided by the invention is formed by coating an enrofloxacin micropill; the enrofloxacin micropill comprises enrofloxacin and auxiliary material and is formed through extruding and rounding; the auxiliary material is any one or more of microcrystalline cellulose, starch, cane sugar, artificial gum, lactose and sodium carboxymethyl starch; according to weight percent, the auxiliary material in the micropill accounts for 70% to 95%; and coating is made of high-molecular enteric material, film forming material, opaquer and the like. The slow-release micropill preparation has the characteristics of slow release and high bioavailability, can be used for treating bacteria and mycoplasma infection of livestocks, and has better curative effect on chronic respiratory diseases, colibacillosis and salmonellosis, and the frequency of medicine taking can be reduced; and in addition, the slow-release micropill provided by the invention has the advantages that the stability of medicine is improved, and peculiar bitter of enrofloxacin can be covered completely, so that feeding intake of the animals is not influenced, and the recovery rate is improved.

The invention relates to the technical field of tea leaf processing and in particular relates to a processing method of dendrobium officinale flower tea. The method comprises the following steps: (1) picking; (2) sorting and shaping; (3) brining; (4) washing; (5) airing; (6) baking and shaping; (7) performing aroma extraction. According to the method, a tea leaf drink capable of being stored for a long time is produced from dendrobium officinale flowers, so that the requirements of people on the different seasons of the dendrobium officinale flowers can be met, the problems of oversupplying during the flowering season of the dendrobium officinale flowers and undersupplying during the non-flowering season of the dendrobium officinale flowers are solved, and the waste of the dendrobium officinale flowers caused by high yield during the flowering period is avoided; the dendrobium officinale flower tea produced by the method can guarantee the medicinal value of the fresh dendrobium officinale flowers, is capable of excellently nourishing yin, moistening the lung, nourishing the stomach, producing body fluid, improving vision and clearing heat after being drunk for a long term, has the effects of improving immunity and resisting ageing, and is good for respiratory diseases, diabetes, chronic hepatitis, chronic gastritis and the like.

The invention relates to an emission reduction dry-type culture method for producing nonreactive pork. The method uses pig feeds, which contain feedstuff additive premix, and active water agent to feed the pigs. An organic adhesive layer is laid inside a pig shed. The active water agent contains natural plant extract and bacillus subtilis, and is drunk by the pigs through a leak protection and filtering water device arranged inside the pig shed. The feedstuff additive premix contains NSP enzyme, micro-ecological agent, plant extract and acidifier. The method can prevent the pigs from having intestinal bacteria and viral diseases and respiratory diseases, and reduce the discharge of fecaluria and living water, harmful gas produced by pig fecaluria and stench, and through which prevents the breeding of flies. At the same time of producing nonreactive port, the method can reduce the pollution caused by excreta.

The invention belongs to the biotechnology application field, and relates to simultaneous detection and genotyping of infections of 16 respiratory viruses (including FluA, FluB, sH1N1, PIV1, PIV2, PIV3, RSVA, RSVB, HRV, HMPV, HBoV, CoV NL63, CoV OC43, CoV 229E, CoV HKU1 and Adv) of nasopharyngeal extract specimens of patients of respiratory-related diseases of all levels of disease prevention and control institutions and sentinel hospitals. Specifically, nucleotide sequences of representative strains of the 16 respiratory viruses are downloaded from NCBI; through literature review and multiple sequence alignment, pathogen relatively-conservative regions are determined, and multiplex specific primers are designed. Single-tube multiplex (18 stages) PCR detection is carried out for detecting the 16 respiratory virus conservative regions, and an entire reaction takes less than 2 hours. According to the invention, a defect that genotyping cannot be carried out with conventional single-tube multiplex fluorescent qualitative PCR detections can be overcome, and defects of complicated operations, long time, and high cost of conventional chip detection methods can be overcome. With the application provided by the invention, a novel idea is provided for respiratory virus genotyping technologies. With characteristics of high specificity, high sensitivity, and high speed, powerful technological support is provided for rapid and accurate screening and genotyping of the respiratory-disease-related viruses. The invention has important significance upon the researches of respiratory-tract patient infection pathogen spectrum of out nation, and upon molecular epidemiological investigations.

The invention discloses a colloidal gold method detection test strip and a reagent kit for an IgG antibody of a respiratory disease and a preparation method of the reagent kit. The test strip determines the IgG antibody by using a principle of an immunocapture method; respiratory herpes viruses, adenoviruses, influenzaviruses and an IgG antibody of mycoplasma pneumoniae can be detected jointly by one operation; the operation process is simplified; the test strip is simple, convenient, rapid and accurate in detection, suitable for mass detection and applicable to primary screening and epidemiological survey; and a result is distinct and easy to distinguish.

This description relates to insight into the asthma management habits of a patient or a plurality of patients. The provided information includes records of rescue medication usage events, records of controller medication events, and overall evaluations of a patients disease management. Users of the application may include both patients who may use the information to monitor their own habits or providers who may use the information to monitor patients or improve a patient's existing medication regimen.

An inhaler device comprising a container for powdered medicament, an inhalation channel, a movable metering member, a depressible actuator and a multiple dosage preventing means for locking the depressible actuator after use such that the actuator is unlocked only upon inhalation. The inhaler device is useful in the treatment of respiratory diseases such as asthma. The multiple dosage preventing means of the device eliminates the risk of unintentional overdosing.

The present invention provides a pressurized metered dose inhaler (pMDI) system, comprising a transparent or partially transparent canister which permits a patient to view the amount of medicament remaining in the pMDI system. The system of the present also comprises a dose counter which counts a dose when a dose is dispensed. The present invention provides a pMDI system which is improved over those currently used for treating respiratory diseases.

The invention discloses a florfenicol compound composition and a preparation method thereof. The composition is composed of florfenicol, azithromycin, tylosin, propylene glycol, dimethyl formamide, alpha-pyrrolidone, anhydrous ethanol and polyvinylpyrrolidone (PVP). The preparation method of the composition comprises steps of: 1) adding dimethyl formamide to florfenicol, stirring and dissolving; and sequentially adding propylene glycol, alpha-pyrrolidone and anhydrous ethanol, and stirring to mix evenly; 2) adding azithromycin and tylosin, and stirring to mix evenly; 3) heating with stirring at 40 DEG C, adding polyethylene pyrrole pyrrolidone, dissolving and continuing to stir for 15min; and 4) filtering the obtained solution, inflating nitrogen and encapsulating to obtain the florfenicol compound composition. The compound composition provided by the invention is mainly used in the treatment of swine respiratory diseases, and especially has specific long-term treatment effect and no recurrence on respiratory diseases, such as infectious pleuropneumonia, Haemophilus parasuis, swine plague and asthma.

The invention relates to the composition of an ambroxol HCl-containing sustained-release pellet and a preparation method. The sustained-release pellet consists of two parts which are a quick-release pellet core and a sustained-release coating film respectively, can achieve the effect of long-term release approaching to zero-order release, is mainly used for treating acute and chronic respiratory diseases, and is a medicament of first choice for dispelling phlegm.